Thrombelastography

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. 
  • A conundrum: general or neuraxial anesthesia and the use of ROTEM. 
  • A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. 
  • A prospective, randomized comparison of thromboelastographic coagulation profile in patients receiving lactated Ringer's solution, 6% hetastarch in a balanced-saline vehicle, or 6% hetastarch in saline during major surgery. 
  • Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. 
  • Anticoagulation and reversal paradigms: is too much of a good thing bad? 
  • Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. 
  • Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII. 
  • Association of weight gain with coronary artery disease, inflammation and thrombogenicity. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bleeding and management of coagulopathy. 
  • Blood Ethanol Levels Are Not Related to Coagulation Changes, as Measured by Thromboelastography, in Traumatic Brain Injury Patients. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Central aortic pulse pressure, thrombogenicity and cardiovascular risk. 
  • Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. 
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. 
  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. 
  • Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: a randomised, controlled study. 
  • Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. 
  • Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. 
  • Fibrinogen and bleeding: old molecule--new ideas. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 
  • Functional maturity of the coagulation system in children: an evaluation using thrombelastography. 
  • Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. 
  • Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. 
  • In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. 
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? 
  • Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. 
  • Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. 
  • Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. 
  • Moderate elevations in international normalized ratio should not lead to delays in neurosurgical intervention in patients with traumatic brain injury. 
  • Nucleic acid scavengers inhibit thrombosis without increasing bleeding. 
  • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. 
  • Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. 
  • Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. 
  • Platelet-mediated thrombolysis in patients with δ-storage pool deficiency: a thrombelastographic analysis. 
  • Point of care devices for assessing bleeding and coagulation in the trauma patient. 
  • Postpartum hemorrhage management in 2012: predicting the future. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. 
  • Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. 
  • Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. 
  • Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. 
  • Rotational thromboelastometry-guided blood product management in major spine surgery. 
  • Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. 
  • The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of ionised magnesium on coagulation using thromboelastography. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. 
  • The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2. 
  • Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. 
  • Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. 
  • Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. 
  • Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke. 
  • Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. 
  • Use of Earlier-Reported Rotational Thromboelastometry Parameters to Evaluate Clotting Status, Fibrinogen, and Platelet Activities in Postpartum Hemorrhage Compared to Surgery and Intensive Care Patients. 
  • Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. 
  • Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? 
  • Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.